Sp192
PANEL DISCUSSION
Date
May 18, 2024
Explore related products in the following collection:
Presenters
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Northwestern University Feinberg School of Medicine
University of California San Diego
University Hospitals Leuven
Tracks
Related Products
NEUTROPHIL EXTRACELLULAR TRAPS ENHANCE PROFIBROTIC ACTIVITY OF INTESTINAL FIBROBLASTS IN CROHN’S DISEASE THROUGH TLR2/NF-KB PATHWAY
BACKGROUND: Neutrophil extracellular traps (NETs) consist of DNA filaments and cytoplasmic protein granules, extruded by neutrophils after PAD4-dependent activation…
FAECAL MICROBIOTA TRANSPLANTATION IN ACTIVE ULCERATIVE COLITIS: INSIGHTS FROM A RANDOMIZED CONTROLLED TRIAL HALTED FOR FUTILITY
INTRO/BACKGROUND Rigorous donor preselection on microbiota level, strict anaerobic processing, and repeated FMT administration were hypothesized to improve FMT outcomes for induction of remission in UC in the RESTORE-UC trial, for which we here report on the clinical results and observed microbial…
REAL-TIME AUTOMATED ASSESSMENT OF HISTOLOGICAL DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS USING SINGLE WAVELENGTH ENDOSCOPY TECHNOLOGY
Assessment of mucosal healing as a key denominator in the treat-to-target strategy for managing ulcerative colitis remains challenging. To address this, objective evaluation of histological disease activity holds promise…
EFFICACY AND SAFETY OF OBEFAZIMOD IN UC PATIENTS AT WEEKS 48 AND 96 OF AN OPEN-LABEL MAINTENANCE STUDY AMONG CLINICAL RESPONDERS AT WEEK 8 OF THE PHASE 2B INDUCTION TRIAL
Obefazimod is an investigational, oral, once-daily, small molecule which enhances expression of microRNA-124 and is currently in phase 3 clinical trials for the treatment of patients with moderately to severely active ulcerative colitis (UC) [1]…
